[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cognitive-impairment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cognitive-impairment":711},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,189,0,25,[9,49,78,106,129,182,212,232,259,291,315,337,366,389,421,444,467,495,523,555,577,606,631,659,689],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100632017",false,"NCT07508215","Efficacy of Bright Light Therapy on Cognitive Impairment in Major Depressive Disorder and Its Neuroimaging Mechanisms: Protocol for a Randomised Controlled Trial","The inclusion and exclusion criteria for MDD patients. 1、Inclusion Criteria:\n\n1. MDD diagnosis according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-Ⅳ), first episode or recurrence, confirmed by an experienced psychiatrist using the Mini International Neuropsychiatric Interview.\n2. Age between 18 and 60 years; and gender no-limited;\n3. The severity of MDD symptoms must be ≥14 scores on the HAMD-17;\n4. With CI currently, defined as a total score of \\\u003C70 on the SC;\n5. A SSRI monotherapy at stable dosages for at least 4 weeks; or medication-free status;\n6. Education level above primary school, able to understand and cooperate in completing the study procedures;\n7. Voluntarily participating in this study and sign the informed consent before enrollment.\n\n2、Exclusion Criteria:\n\n1. Current or past diagnosis of any disorder other than MDD according to DSM-Ⅳ criteria;\n2. The scores on the Young Mania Rating Scale (YMRS) are\\>8;\n3. The participants who have undergone other intervention in addition to SSRIs whinin the past 6 months or now, or who plan to do that in 1 month;\n4. The participants with strong self-blame, self-harm, or suicidal risks (the HAMD-17 suicide item score of ≥3);\n5. The participants with severe physical illnesses, including heart failure, renal failure, severe liver dysfunction, hyperthyroidism, or hypothyroidism; Or a history of severe brain trauma or organic brain pathology (e.g., intracerebral hemorrhage, large-area cerebral infarction, encephalitis, epilepsy), as well as neurological diseases;\n6. The participants with any degree of retinal pathology, including retinal dystrophy, age-related macular degeneration, diabetic retinopathy, cataracts, glaucoma, or other ocular diseases;\n7. The participants with photosensitive conditions, such as systemic lupus erythematosus, porphyria, chronic photodermatitis, solar urticaria, or those currently receiving medications that may increase photosensitivity (e.g., phenothiazines, antimalarials, propranolol, hypericin, stimulants, or chronic treatment with nonsteroidal anti-inflammatory drugs);\n8. Pregnant or lactating women;\n9. The participants with contraindications to MRI, such as the presence of non-MRI-safe metallic implants or claustrophobia;\n10. The participants deem unsuitable for inclusion in this study by the investigator for other reasons.\n\nWithdrawal and Termination Criteria：\n\n1. The participants meet one of the exclusion criteria above after enrollment;\n2. When the participants' treatment regimen need change;\n3. The participants who fail to cooperate or voluntarily withdraw from the study;\n4. Due to severe adverse events, the patients are unable to tolerate phototherapy;\n5. The participants who fail to adhere to the study protocol intervention for three consecutive days or for a cumulative duration exceeding seven days;\n6. Cancellation of the study.\n\nThe inclusion and exclusion criteria for Health controls\n\n1\\. Inclusion criteria\n\n1. Age between 18 and 60 years; and gender no-limited;\n2. Without CI currently, defined as a total score of ≤ 70 on the SC;\n3. Education level above primary school, able to understand and cooperate in completing the study procedures;\n4. Voluntarily participating in this study and sign the informed consent before enrollment.\n\n2.Exclusion criteria\n\n1. Current or past diagnosis of any psychiatric disorders, or history of substance\u002Fdrug abuse or dependence;\n2. Current or past diagnosis of severe somatic diseases, such as heart failure, renal failure, severe liver dysfunction, or hyperthyroidism\u002Fhypothyroidism;\n3. History of severe traumatic brain injury or organic brain lesions;\n4. Pregnant or lactating women;\n5. The participants with contraindications to MRI, such as the presence of non-MRI-safe metallic implants or claustrophobia.\n6. The participants deem unsuitable for inclusion in this study by the investigator for other reasons.",true,"ALL","18 Years","60 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to validate the therapeutic efficacy and safety of bright light therapy (BLT) in ameliorating cognitive impairment (CI) in major depressive disorder (MDD), characterize the functional and structural features of the hippocampus (HPC)-dorsolateral prefrontal cortex (dlPFC) neural circuitry in MDD participants with CI and examine the mediating effect of the HPC-dlPFC neural circuit on CI induced by BLT treatment in MDD participants. MDD participants will be required to only receive selective serotonin reuptake inhibitors (SSRIs) as monotherapy for at least four weeks, or medication-free status before enrollment. Eligible participants will be randomly assigned to the experimental group and the control group. The experimental group will receive the intervention of BLT, and the control group will receive the intervention of dim red light (DRL). The intervention will last for four weeks, 6 days per week, with 40 minutes each day between 7 am and 10 am. The MDD participants will be followed once in the end of each week during the 4-week intervention and in the end of the 4th week after intervention. Demographic information will be collected at baseline; cognitive function will be evaluated at baseline, weeks 2, 4, and 8 after intervention beginning; and other symptoms such as depression, anxiety and sleep were assessed at baseline, weeks 1, 2, 3, 4, and 8 after intervention beginning. Moreover, structural and functional MRI scans will be made at baseline and post-intervention. During the intervention, MDD participants will be required to keep a record of daily light exposure duration and complete the daily sleep diary as well.",[27,28,29,30],"Major Depressive Disorder (MDD)","Neuroimaging","Bright Light Treatment","Cognitive Impairment",[32,28,33,34,30,35],"Major Depressive Disorder","Magnetic Response Imaging","Bright Light Therapy","Randomized Controlled Trial","RECRUITING","2026-06-28",{"date":39,"type":40},"2026-06-30","ACTUAL",{"date":42,"type":40},"2026-02-08",{"date":44,"type":21},"2028-12-31",{"name":46,"class":47},"Peking University Sixth Hospital","OTHER",2,{"id":50,"slug":4,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100645122","NCT07678918","Cognitive Function and Quality of Life in Obstructive Sleep Apnea","Correlation Between the Cognitive Function and Quality of Life in Patients With OSA","Inclusion Criteria:\n\n* Patients Group: Age \\> 18 years.\n* Patients Group: Meeting the AASM diagnostic criteria for OSA.\n* Control Group: Age and sex-matched community members related to the patients.\n* Control Group: Education level, social status, and comorbidity-matched people.\n\nExclusion Criteria:\n\n* Patients Group: OSA patients who are compliant on PAP therapy (\\> 4 hours, \\> 5 nights\u002Fweek) for ≥ 6 months.\n* Patients Group: Inability to comprehend and\u002For co-operate with the instructions provided by the investigators during neurocognitive function assessment.\n* Patients Group: History of neurological comorbidities with potential cognitive impairment (previous cerebrovascular stroke, dementia).\n* Patients Group: Patients who are maintained on medications that potentially impair cognitive performance (histamine receptor antagonist, antipsychotic, antidepressant, or mood stabilizer drugs).\n* Patients Group: Use of alcohol, or illicit drugs that interfere with cognitive function (cannabis, opioids, amphetamine or equivalents).\n* Control Group: Intermediate or high-risk of having undiagnosed OSA as assessed by the STOP-BANG questionnaire.",{"count":56,"type":21},86,"OBSERVATIONAL","Obstructive Sleep Apnea (OSA) is a common condition that disrupts normal breathing during sleep. Beyond causing daytime tiredness, OSA can also impact a person's cognitive functions, such as their attention span, memory, and problem-solving skills, which may in turn affect their overall quality of life.\n\nThe main purpose of this study is to compare the thinking and memory skills of adults recently diagnosed with OSA against a control group of healthy adults without the condition. Furthermore, the researchers aim to understand how specific cognitive challenges (like difficulty sustaining attention) relate to a patient's physical and mental well-being.\n\nParticipants in the study will undergo an overnight sleep test (diagnostic polysomnography) at a sleep clinic. Shortly after the sleep test, participants will complete a series of short, computer-based tasks designed to measure their attention, memory, and executive function. They will also be asked to fill out standard questionnaires regarding their daily sleepiness, mood, and health-related quality of life.",[60,30,61],"Obstructive Sleep Apnea","Quality of Life",[60,63,61,64,65,66,67],"Cognitive Function","Neurocognitive Impairment","Psychomotor Vigilance","Polysomnography","SF-36","NOT_YET_RECRUITING","2026-06-25",{"date":71,"type":40},"2026-07-01",{"date":73,"type":21},"2026-08",{"date":75,"type":21},"2027-09",{"name":77,"class":47},"Assiut University",{"id":79,"slug":4,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":15,"sex":16,"minAge":18,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100515939","NCT05998031","A Mechanistic Study to Investigate tDCS and Working Memory in MCI Patients","AIM","Inclusion Criteria\n\n* Age 60-95 years\n* Montreal Cognitive Assessment (MoCA) score 18 and above (scores will be adjusted for education)\n* Able to receive electrical stimulation\n* Ability to comprehend conversational voices\n* Adequate motor capacity to operate computer mouse and click-button in-scanner\n* Ability to participate in the intervention and attend training sessions Exclusion Criteria\n* Failure to provide informed consent\n* Contraindications to MRI recording (e.g., any kind of ferrous metallic stents or ferrous metal objects in the body, heart valve prosthesis, or other metal implants, claustrophobia, neurostimulation system, defibrillator, pacemaker, or other implanted device)\n* Left-handed, or left hand dominant\n* History of neurological, seizures, and psychiatric disorders, traumatic brain injury, incidence of stroke involving large vessel\n* Terminal illness with life expectancy less than 12 months, as determined by physician\n* Brain tumor or malformation or any foreign body known or previously identified in brain\n* Cancer in active treatment, besides skin cancer\n* Currently on GABAergic or glutamatergic medications, or on calcium or sodium channel blockers, which alter or block the ability of tDCS to facilitate tissue excitability\n* Unable to communicate because of severe hearing loss or speech disorder\n* Severe sensory impairment\n* Inability to communicate in English\n* Severe visual impairment, which would preclude completion of the assessment and\u002For intervention\n* No physical impairment precluding motor response or lying still for an hour in the scanner that could confound study findings\n* Moderate-to-severe depressive symptoms as defined by scoring 10 or above on the Geriatric Depression Scale (GDS)","95 Years",{"count":86,"type":21},110,[24],"The current study is a mechanistic study to evaluate working memory gains from application of transcranial direct current stimulation (tDCS) in older adults with mild cognitive impairments (MCI) compared to cognitively healthy control",[30,90],"Cognitive Decline",[92,93,94,95,96],"Cognitive Aging","Brain Stimulation","functional MRI","Computational Modeling","Finite Element Method (FEM)",{"date":98,"type":40},"2026-06-26",{"date":100,"type":40},"2024-04-24",{"date":102,"type":21},"2029-11-30",{"name":104,"class":47},"University of Florida",1,{"id":107,"slug":4,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":124,"completionDateStruct":125,"leadSponsor":127,"locationsCount":105},"100644949","NCT07676864","Eye Tracking for Early Identification of Post-ICU Cognitive Impairment","Early Identification of Post-ICU Cognitive Impairment Using Eye-Tracking Technology: A Prospective Observational Study","Inclusion Criteria:\n\n* Successfully transferred from the ICU to a general ward after ICU treatment.\n* ICU length of stay of at least 24 hours.\n* Conscious and able to cooperate with cognitive assessment and eye-tracking tests.\n* Willing to participate in the study and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Diagnosed with cognitive impairment before ICU admission, such as Alzheimer's disease, based on medical history or previous medical records.\n* Previous diagnosis of mental illness or intellectual developmental disorder.\n* Severe visual, hearing, or eye disease that prevents completion of cognitive assessment or eye-tracking tasks.\n* Severe neurological disease that may affect cognitive function, such as stroke, traumatic brain injury, or intracranial infection.\n* Unable to understand or complete the cognitive assessment or eye-tracking tasks due to severe fatigue, marked inattention, communication disorder, or other reasons as assessed by the research staff.",{"count":113,"type":21},73,"Some patients may have problems with memory, attention, thinking speed, or other cognitive functions after leaving the intensive care unit (ICU). This is called post-ICU cognitive impairment. Early recognition of this problem may help clinicians provide follow-up care and support more promptly.\n\nThis study will explore whether eye-tracking technology can help identify cognitive impairment in patients soon after ICU discharge. Eye tracking is a non-invasive test that records eye movements while a person looks at images or completes simple visual tasks on a screen. The test does not involve any treatment or change in usual medical care.\n\nParticipants will be adult patients who have been transferred from the ICU to a general ward. Within 7 days after ICU discharge, participants will complete a cognitive assessment and an eye-tracking test. The study team will also collect relevant clinical information from medical records. Patients will be grouped according to whether they have post-ICU cognitive impairment based on cognitive assessment and clinical judgment.\n\nThe main purpose of this study is to assess whether information obtained from eye-tracking tests can help clinicians identify possible post-ICU cognitive impairment at an early stage, when used together with standard cognitive assessment. The study will also compare eye movement patterns between the two groups and explore whether eye-tracking measures add useful information beyond standard cognitive assessment.",[116,30],"Post Intensive Care Syndrome (PICS)",[118,30,119,120,121],"Eye Tracking","Cognitive Assessment","Intensive Care Unit","Post intensive Care Syndrome","2026-06-24",{"date":39,"type":40},{"date":73,"type":21},{"date":126,"type":21},"2027-05",{"name":128,"class":47},"Shanghai Zhongshan Hospital",{"id":130,"slug":4,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":139,"conditions":140,"keywords":166,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":173,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":181},"100270060","NCT02795052","Neurologic Stem Cell Treatment Study","Neurologic Bone Marrow Derived Stem Cell Treatment Study","NEST","Inclusion Criteria:\n\n1. Have documented functional damage to the central or peripheral nervous system unlikely to improve with present standard of care.\n2. Be at least 6 months post-onset of the disease.\n3. If under current medical therapy (pharmacologic or surgical treatment) for the condition be considered stable on that treatment and unlikely to have reversal of the associated neurologic functional damage as a result of the ongoing pharmacologic or surgical treatment.\n4. In the estimation of Dr. Weiss and the neurologists have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.\n5. Be over the age of 18 and capable of providing informed consent.\n6. Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure. Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.\n\nExclusion Criteria:\n\n1. All patients must be capable of an adequate neurologic examination and evaluation to document the pathology. This will include the ability to cooperate with the exam.\n2. Patients must be capable and willing to undergo follow up neurologic exams with the sub-investigators or their own neurologists as outlined in the protocol.\n3. Patients must be capable of providing informed consent.\n4. In the estimation of Dr. Weiss the BMSC collection and treatment will not present a significant risk of harm to the patient's general health or to their neurologic function. .\n5. Patients who are not medically stable or who may be at significant risk to their health undergoing the procedure will not be eligible.\n6. Women of childbearing age must not be pregnant at the time of treatment and should refrain from becoming pregnant for 3 months post treatment.",{"count":137,"type":21},500,[24],"This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1\u002F3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http:\u002F\u002Fmdstemcells.com\u002Fnest\u002F",[141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,30,165],"Neurologic Disorders","Nervous System Diseases","Neurodegenerative Diseases","Neurological Disorders","Stroke","Traumatic Brain Injury","Cadasil","Chronic Traumatic Encephalopathy","Cerebral Infarction","Cerebral Ischemia","Cerebral Stroke","Cerebral Hemorrhage","Parkinson","Multi-System Degeneration","MSA - Multiple System Atrophy","Progressive Supranuclear Palsy","ALS","Amyotrophic Lateral Sclerosis","Neuropathy","Diabetic Neuropathies","Alzheimer Disease","Dementia","Frontotemporal Dementia","Lewy Body Disease","Lewy Body Variant of Alzheimer Disease",[167,168,145,146,169,170,159,171,150,30,162,172],"Neurologic Disease","Cerebral Vascular Accident","Multiple Sclerosis","Parkinsons Disease","Diabetic Neuropathy","Neurodegeneration",{"date":98,"type":40},{"date":175,"type":40},"2016-06",{"date":177,"type":21},"2028-07-31",{"name":179,"class":180},"MD Stem Cells","INDUSTRY",3,{"id":183,"slug":4,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":188,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":22,"phases":192,"briefSummary":193,"conditions":194,"keywords":196,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":4},"100626406","NCT07435220","Robot-Assisted Meditation for Older Adults With Cognitive Concerns","Investigating the Effects of Haptic Robot Meditation on Sleep Quality in Older Adults With Cognitive Concerns","Inclusion Criteria:\n\n* Participants have subjective cognitive decline, assessed using the Subjective Cognitive Decline Questionnaire (SCD-Q)\n\nExclusion Criteria:\n\n* Participants do not have dementia or mild cognitive impairment.\n* To exclude significant cognitive impairment, investigators will utilize the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA).","65 Years","80 Years",{"count":191,"type":21},100,[24],"While traditional app-based mindfulness meditation programs relying solely on audio guidance have shown potential benefits for older adults, the apps often face challenges such as low compliance. Participants frequently report difficulties in maintaining focus during meditation sessions, which can limit its effectiveness in improving outcomes such as stress reduction and sleep quality. Recognizing these limitations, this study explores whether a haptic-enabled handheld robot can enhance meditation practices by providing both haptic and audio guidance. The robot, designed to foster sustained attention and encourage rhythmic breathing, may offer a novel, multidimensional approach that addresses compliance issues and supports deeper engagement in mindfulness meditation.\n\nThe study primarily seeks to answer the question: Does robot-guided meditation, combining both haptic and audio guidance, improve the sleep quality of older adults living alone with subjective cognitive decline more effectively than traditional audio-based mindfulness meditation guidance? Furthermore, the study examines a secondary question: Is the effect of robot-guided meditation on sleep quality mediated by reductions in stress? By investigating these questions, the research aims to offer insights into whether haptic-enabled meditation technology can overcome common barriers to mindfulness practices among older adults and serve as an innovative tool to improve physical, emotional, and cognitive well-being.",[30,195],"Sleep",[197,198,199,200,201,202],"Meditation","Robot","Older adults","Cognitive concerns","Robot-Guided Intervention","Audio-Guided Control","2026-06-22",{"date":205,"type":40},"2026-06-23",{"date":207,"type":21},"2026-11-01",{"date":209,"type":21},"2027-12-31",{"name":211,"class":47},"Johns Hopkins University",{"id":213,"slug":4,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":218,"enrollmentInfo":219,"targetDuration":4,"studyType":22,"phases":221,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":225,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":105},"100605359","NCT07161492","Brain Functional Connectivity Mechanism of Cognitive Flexibility Impairment and rTMS Intervention in Major Depressive Disorder","Individualized Dual-Target Repetitive Transcranial Magnetic Stimulation (rTMS) Targeting Left Inferior Parietal Lobule and Right Dorsolateral Prefrontal Cortex Functional Connectivity for Cognitive Flexibility Impairment in Major Depressive Disorder: A Randomized, Double-Blind-Controlled Trial","Inclusion Criteria:\n\nMeet DSM-5 criteria for major depressive episode confirmed by the Structured Clinical Interview for DSM-5 Disorders (SCID-5), with no prior manic or hypomanic episodes; diagnosed as major depressive disorder without psychotic features by two attending psychiatrists.\n\nFirst episode or recurrent, currently in a depressive episode (HAMD\\_17≥17).\n\nAge 18 to 45 years, all sexes and genders. Han Chinese, right-handed. Junior high school education or above, no color blindness, able to understand and provide informed consent, and complete assessments and tests.\n\nWilling to participate voluntarily and sign written informed consent.\n\nExclusion Criteria:\n\nMeet DSM-5 diagnostic criteria for any psychiatric disorder other than major depressive disorder.\n\nReceived non-pharmacological treatments within the past 6 months, such as electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), or systematic psychotherapy (≥ 10 sessions).\n\nPrior treatment with CCRT. Received antipsychotics or other medications affecting cognitive function within the past month, or cholinergic agents (e.g., donepezil, galantamine) within 14 days, memantine within 20 days, or other racetam drugs (e.g., piracetam) within 2 days prior to randomization.\n\nOrganic brain disorders or severe physical illnesses (e.g., thyroid disease, lupus erythematosus, diabetes, liver\u002Fkidney\u002Flung impairment, infection, major trauma).\n\nHistory of traumatic brain injury with loss of consciousness or other conditions that may interfere with this study.\n\nHistory of alcohol or substance abuse or dependence. Severe suicidal ideation or suicide attempt . Currently receiving hormonal therapy. Pregnancy, lactation, possibility of pregnancy, or planned pregnancy. History of epilepsy or family history of epilepsy. Implanted metal materials in the body (e.g., pacemaker, dental implants, metal intrauterine device).\n\nAny other factors that, in the investigator's opinion, place the participant at potential risk or interfere with the study participation.","45 Years",{"count":220,"type":21},105,[24],"Major depressive disorder (MDD) often involves cognitive deficits, particularly in cognitive flexibility, which is inadequately addressed by standard antidepressants. This study tests an innovative brain stimulation regimen: individualized dual-target repetitive transcranial magnetic stimulation (rTMS) to improve cognitive flexibility in MDD patients.\n\nThis is a randomized, double-blind, sham-controlled trial that plans to enroll 105 MDD patients with cognitive flexibility impairment. Participants will be randomly assigned to one of three groups: (1) Active dual-target group - receiving active rTMS over both the left inferior parietal lobule (IPL) and the right dorsolateral prefrontal cortex (DLPFC); (2) Active single-target group - receiving active rTMS over the left IPL and sham stimulation over the right DLPFC; (3) Sham control group - receiving sham stimulation over both targets. All participants will continue their stable antidepressant medication (SSRI or SNRI). The rTMS intervention lasts 10 days, with 5 stimulation sessions per day.\n\nCognitive flexibility, depressive symptoms, and brain functional connectivity will be assessed at baseline, immediately after the 10-day treatment, and at 2-week and 4-week follow-ups using neurocognitive tests, clinical rating scales (e.g., HAMD), and functional MRI. The results will help confirm the role of the IPL-DLPFC connectivity in cognitive flexibility and may establish a new treatment target for cognitive dysfunction in MDD.",[224,30],"Depressive Disorder, Major",{"date":69,"type":40},{"date":227,"type":21},"2026-07",{"date":229,"type":21},"2028-10",{"name":231,"class":47},"Second Xiangya Hospital of Central South University",{"id":233,"slug":4,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":239,"targetDuration":4,"studyType":22,"phases":241,"briefSummary":242,"conditions":243,"keywords":245,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":4},"100641118","NCT07658287","Immersive Virtual Reality for Older Adults in Long-Term Care Settings","Use of Immersive Virtual Reality in Long-Term Care Facilities and Seniors' Homes in Quebec","VR-LTC","Inclusion Criteria:\n\nFor resident participants:\n\n* Resident of a participating long-term care facility, seniors' home, or alternative seniors' home in the Chaudière-Appalaches or Capitale-Nationale regions of Quebec\n* Aged 60 years or older\n* Able to understand French or English\n* Able to provide informed consent or assent, or have consent provided by a legally authorized representative or person authorized to consent\n* Mild to moderate cognitive impairment or neurocognitive disorder\n* Normal or corrected vision and hearing\n\nFor staff participants:\n\n* Regularly works with at least one resident participating in Phase 3\n* Has completed the revised virtual reality training provided by Super Splendide and\u002For Martine Bordeleau\n\nExclusion Criteria:\n\nFor resident participants:\n\n* Recurrent migraines\n* Epilepsy\n* Traumatic brain injury during the past year\n* Glaucoma or recovery from eye surgery\n* Diagnosed uncontrolled epilepsy\n* Diagnosed severe vertigo\n* Severe hearing impairment without a corrective hearing device\n* Significant visual impairment that would prevent use of a virtual reality headset\n* Motion sickness that would prevent use of a virtual reality headset\n* Any health condition that restricts movement or prevents safe participation, such as a significant reduction in neck or upper-limb range of motion",{"count":240,"type":21},36,[24],"The goal of this clinical trial is to learn if an immersive virtual reality mindfulness meditation program is feasible and acceptable for older adults living in long-term care settings in Quebec who have mild to moderate neurocognitive disorder. It will also learn about the safety and potential effects of the program on well-being.\n\nThe main questions it aims to answer are:\n\n* Is the virtual reality mindfulness meditation program feasible and acceptable for residents and staff in long-term care settings?\n* Does the adapted version of the program show potential benefits for well-being, including depression, anxiety, quality of life, mindfulness, pain, and loneliness?\n* What practical challenges, user experiences, and side effects, such as cybersickness, occur during the program?\n\nResearchers will compare the original Toujours Dimanche virtual reality mindfulness meditation program, an adapted version of Toujours Dimanche designed for older adults with mild to moderate neurocognitive disorder, and standard care alone to see if the adapted program is feasible, acceptable, and potentially helpful.\n\nParticipants will:\n\n* Take part in up to 8 virtual reality mindfulness meditation sessions over 4 weeks, if assigned to a virtual reality group\n* Complete questionnaires before and after the 4-week study period\n* Share feedback about their experience, when possible\n* Be observed by staff or research team members to document feasibility, acceptability, user experience, and safety",[30,244],"Long-term Care Centres for Old Adults Users",[246,247,248,249,30],"Virtual Reality","Mindfulness Meditation","Long-Term Care","Older Adults","2026-06-16",{"date":252,"type":40},"2026-06-18",{"date":254,"type":21},"2026-06-15",{"date":256,"type":21},"2027-06-15",{"name":258,"class":47},"Laval University",{"id":260,"slug":4,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":22,"phases":267,"briefSummary":268,"conditions":269,"keywords":277,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":105},"100633163","NCT07523113","ME\u002FCFS Brain Fog: Cognitive Rehabilitation Trial","Brain Training for Chronic, Post-viral, Brain Fog: Study A","Inclusion Criteria:\n\n* diagnosis of ME\u002FCFS that preceded cognitive complaints\n* mild or greater cognitive impairment\n* moderate or greater brain fog\n* some impairment in the performance of daily activities\n* ≥ 18 years, no upper limit if medically stable\n* reside in the community (as opposed to a hospital or skilled nursing facility)\n* able to travel to the laboratory on multiple occasions\n* has Internet service\n* has a personal computer, laptop, or tablet that can access the Internet\n* sufficiently fit, from both a physical and mental health perspective, to take part in the study\n* adequate sight and hearing to complete the UFOV test\n* adequate thinking skills, e.g., ability to follow directions and retain information to complete UFOV and CTAL, as marked by the judgement of the screener that the candidate is able to adequately complete the UFOV and CTAL\n* sufficient English proficiency (i.e., ability to speak, understand, read, and write to take part in study activities)\n\nExclusion Criteria:\n\n* cognitive impairment due to a developmental disability, psychiatric disorder, or substance abuse, or due to another type of brain injury, such as traumatic brain injury, stroke, or a progressive brain disease, such as Alzheimer's Dementia\n* current substance abuse disorder\n* diagnosis of postural orthostatic tachycardia syndrome (POTS) by a healthcare provider\n* prior cognitive processing speed training on DoubleDecision or a similar program\n* cannot tolerate taVNS\n* prior history of heart attack or other serious cardiac events\n* implanted medical device of any type\n* vasovagal syncope or history of fainting\n* history of seizures or epilepsy\n* temporomandibular Joint (TMJ) syndrome or other conditions that cause substantial jaw pain\n* history of peripheral nerve injury to the head, neck, or face\n* pregnant or breastfeeding\n* not able or willing to get an MRI scan\n* not able or willing to get a blood draw",{"count":266,"type":21},30,[24],"The purpose of this study is to compare two approaches to cognitive rehabilitation in adults with post-viral cognitive syndrome, which resulted in brain fog. All participants will be screened for eligibility prior to participation. Most of the procedures will take place over a phone call or secure telehealth platform (i.e., Zoom). However, participants will be asked to visit UAB on three occasions for blood sample collection and brain imaging (about 2 hours each). Online testing will happen one month before treatment, one day before treatment, one day afterwards, and 6 months afterwards. The study will utilize two different forms of rehabilitation training to improve participants' cognitive ability. Participants will be randomized to one of the two treatment groups. The first treatment approach, known as Constraint-Induced Cognitive Therapy (CICT), will feature (A) web-based computer \"games\" that trains how quickly individuals process information that they receive through their senses; (B) online training on everyday activities with important cognitive components, (C) procedures designed to transfer improvements in cognition from the treatment setting to everyday life, and (D) a non-invasive form of vagus nerve stimulation, also known as trans-auricular VNS (taVNS). The second approach, known as Brain Fitness Training (BFT), will include (A) web-based computer \"games\" that train reaction time and eye-hand coordination; (B) in-lab training on relaxation, breathing, healthy nutrition, and healthy sleep, (C) education about how relaxation, breathing, nutrition, and sleep are connected to thinking effectiveness, and (D) taVNS. Approximately 30 hours of training will be conducted over a secure telehealth platform (i.e., Zoom) in the span of two- to four- weeks. A typical CICT session will consist of one hour of gaming, with the bulk of the session being spent on cognitive training of the target behaviors and procedures designed to promote transfer of therapeutic gains to daily life. ta-VNS will be administered for 10 minutes before gaming and in-lab target behavior training. A typical BFT session will consist of one hour of gaming, training on healthy lifestyle behaviors (i.e., healthy sleep, nutrition, and relaxation habits), as well as procedures designed to promote transfer of behavior changes to daily life. Ta-VNS will be administered for 10 minutes before gaming and in-lab target behavior training. Training sessions in both conditions will be scheduled based on participants' availability, with the options for sessions scheduled to be as close as every weekday over 2 weeks or as loosely as every other weekday (i.e., over a 4-week span). If a caregiver is available, they will receive training on how to best support participants in their therapeutic program. After the training ends, both groups will receive 4 follow-up phone calls approximately one week apart to promote integration of the gained skills into everyday life. Outcomes measured will include cognitive processing speed, cognitive function on laboratory tests, and spontaneous performance of everyday activities with important cognitive components in daily life.",[270,271,272,273,274,275,30,276],"ME\u002FCFS","ME\u002FCFS Following EBV-associated Infectious Mononucleosis","ME\u002FCFS Following COVID-19","Chronic Fatigue","Chronic Fatigue Syndrome (CFS)","Brain Fog","Cognitive Dysfunction",[270,273,278,30,276,279,280,281],"Brain fog","post-viral syndrome","Cognitive Rehabilitation","CICT","2026-06-04",{"date":284,"type":40},"2026-06-08",{"date":286,"type":21},"2026-06",{"date":288,"type":21},"2028-06",{"name":290,"class":47},"University of Alabama at Birmingham",{"id":292,"slug":4,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":22,"phases":299,"briefSummary":301,"conditions":302,"keywords":306,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":311,"leadSponsor":313,"locationsCount":105},"100638812","NCT07610343","Intranasal Dexmedetomidine-esketamine on Sleep and Cognition in Older Adults With Mild-to-moderate Cognitive Impairment","Impact of Intranasal Dexmedetomidine-esketamine on Sleep Quality and Cognitive Function in Older Adults With Mild-to-moderate Cognitive Impairment: a Randomized, Double-blind, and Placebo-controlled Trial","Inclusion Criteria:\n\n1. Aged ≥ 60 years.\n2. Meeting the clinical diagnostic criteria for Alzheimer's disease, with mild cognitive impairment (MoCA score 18-25) or moderate cognitive impairment (MoCA score 10-17) due to Alzheimer's disease.\n3. Comorbid with sleep disorders (Pittsburgh Sleep Quality Index \\[PSQI\\] score ≥ 7).\n4. Signed informed consent.\n\nExclusion Criteria:\n\n1. Cognitive impairment\u002Fdementia due to other causes (e.g., vascular dementia, frontotemporal dementia, Parkinson's disease dementia).\n2. Unsuitable for intranasal administration due to nasal cavity diseases (e.g., rhinitis, nasal polyps, or nasal congestion of any cause).\n3. Inability to communicate due to visual, auditory, language, or other reasons, or Mini-Mental State Examination (MMSE) score ≤ 9 or MoCA score ≤ 9.\n4. History of schizophrenia, epilepsy, or Parkinson's disease, or confirmed diagnosis of glaucoma, hyperthyroidism, pheochromocytoma, or myasthenia gravis.\n5. Confirmed diagnosis of restless legs syndrome or sleep apnea, or judged to be at high risk of moderate-to-severe sleep apnea according to STOP-Bang score, or Body Mass Index (BMI) \\> 30 kg\u002Fm2.\n6. History of stroke or transient ischemic attack within 12 months prior to enrollment, confirmed intracranial aneurysm, or elevated intracranial pressure from any cause.\n7. Uncontrolled hypertension (e.g., hypertensive crisis or systolic blood pressure \\> 160 mmHg and\u002For diastolic blood pressure \\> 100 mmHg prior to enrollment), myocardial infarction, unstable angina, revascularization surgery within 12 months prior to enrollment, or NYHA class III.\n8. Sick sinus syndrome, severe sinus bradycardia (heart rate \\\u003C 50 beats\u002Fmin), atrioventricular block above degree II without a pacemaker, corrected QT interval (Fridericia-corrected QTcF) ≥ 450 ms, or other severe arrhythmias (e.g., frequent premature ventricular contractions).\n9. Uncontrolled diabetes (e.g., HbA1c \\> 9%, diabetic ketosis, hyperglycemic coma, or hypoglycemia).\n10. Severe hepatic dysfunction (Child-Pugh Class C), renal dysfunction (eGFR ≤ 30 ml\u002Fmin\u002F1.73m2), respiratory insufficiency (SpO2 \\\u003C 93% on room air), or other severe diseases (e.g., frailty with inability to walk independently, advanced-stage tumors).\n11. Alcohol or drug dependence (manifested as strong cravings, uncontrolled use, and withdrawal symptoms upon cessation), or use of contraindicated medications.\n12. Major surgery under general anesthesia within 12 weeks prior to enrollment, or planned surgery within 12 weeks.\n13. Allergy to dexmedetomidine and\u002For esketamine.\n14. Participation in other interventional clinical studies.\n15. Any other conditions deemed unsuitable for study inclusion by the investigator.",{"count":298,"type":21},60,[300],"PHASE4","Patients with cognitive decline are frequently comorbid with sleep disorders which may in turn aggravate cognitive decline. Sedative dose dexmedetomidine improved sleep quality but incresed bradycardia and hypotension; low dose dexmedetomidine produce less side effects, but the sleep promoting effects are relatively weak. Low dose esketamine also has sleep-promoting effects but may produce neuropsychiatric side effects. Both dexmedetomidine and esketamine are approved for intranasal administration. We suppose that intranasal administration of dexmedetomidine-esketamine combination may improve sleep quality and therefore cognitive function in older ptients with Alzheimer's disease cognitive impairment and sleep disorders.",[249,30,303,304,305],"Sleep Disorders","Dexmedetomidine","Esketamine",[249,30,303,304,305],"2026-05-28",{"date":309,"type":40},"2026-06-01",{"date":286,"type":21},{"date":312,"type":21},"2027-12",{"name":314,"class":47},"Peking University First Hospital",{"id":316,"slug":4,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":4,"eligibilityCriteria":320,"healthyVolunteers":15,"sex":16,"minAge":188,"maxAge":4,"enrollmentInfo":321,"targetDuration":4,"studyType":22,"phases":323,"briefSummary":324,"conditions":325,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":48},"100524370","NCT06107842","Effect of Gerofit Exercise on Cognition in Older Veterans","Relationship of Exercise Frequency, Intensity, and Fitness to Improved Cognition and Biomarkers in Gerofit Participants","Inclusion Criteria:\n\n* All Veterans eligible for VA Gerofit program 65 years and older\n* Clearance by PCP to participate in Gerofit exercise program\n\nExclusion Criteria:\n\n* Inability to perform ADLs\n* Significant cognitive impairment\n* Inability to function independently without assistance\n* Unstable angina; proliferative diabetic retinopathy\n* Oxygen dependent\n* Unwillingly to commute and\u002For not able to provide own transportation to Gerofit\n* Incontinence\n* Open wounds\n* Volatile behavioral issue or unable to work successfully in a group environment\u002Fsetting\n* Active substance abuse\n* Homelessness",{"count":322,"type":21},150,[24],"Over 50% of the Veterans enrolled for VA health care are over the age of 65. Dementia prevalence increases with age, and with the increase in the population of people ages 65 and older, the total number of people with dementia is also increasing. Older Veterans often have comorbid PTSD, major depression and traumatic brain injury so that they are at 2 to 5 times the risk for cognitive impairment and dementia compared to the general population. There is evidence that exercise interventions in sedentary older adults could improve both physical and cognitive function. However, there have been very few studies on the effects of exercise on cognition in older Veterans and do not reflect the broader ethnic and health-status diversity of Veterans. Thus, improved knowledge of the role of exercise on cognition as well as the predictive power of biomarkers could have a major beneficial impact on Veterans' functional independence and quality of life. The investigators hypothesize that participation in the VA Gerofit exercise program will improve cognitive function in older Veterans and that blood and muscle biomarkers will predict these improvements.",[326,30,327],"Aging","Physical Activity",{"date":329,"type":40},"2026-06-02",{"date":331,"type":40},"2024-04-01",{"date":333,"type":21},"2029-03-31",{"name":335,"class":336},"VA Office of Research and Development","FED",{"id":338,"slug":4,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":340,"acronym":341,"eligibilityCriteria":342,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":343,"targetDuration":4,"studyType":22,"phases":345,"briefSummary":346,"conditions":347,"keywords":351,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":105},"100639248","NCT07610655","Effects of Transcutaneous Vagal Nerve Stimulation on Post-Surgical Return to Consciousness, Delirium, and Depression","tVNS","Inclusion Criteria:\n\n1. Aged \\> 18 years of age\n2. Patients undergoing lumbar surgery for degenerative disc disease or spinal stenosis involving two or more levels\n3. Montreal Cognitive Assessment (MoCA) score ≥ 18 - accept mild\n4. Ability to use a keyboard\n5. Able to understand and communicate in English\n6. Be able to consent independently\n7. Women of child-bearing age must be comfortable confirming a negative pregnancy prior to participating in the study.\n8. Must not be involved in any other research intervention study testing neurobehavioral functioning\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years of age\n2. History of vagotomy (cutting the vagus nerve)\n3. History of bradycardia, heart block, prolonged QT syndrome, brugada syndrome, heart failure with ejection fraction less than 35% and\u002For New York Heart Association symptoms\n4. MoCA \\\u003C 18\n5. History of seizure disorder or intracranial hemorrhage\n6. Patients with carotid stenosis\n7. Patients with aneurysms\n8. Other neurological diagnoses or a diagnosis of severe psychiatric disorder (e.g., psychosis) or a reported childhood learning disability\n9. Pregnancy, breastfeeding\n10. Active addiction history\n11. ECG adhesive allergy\n12. Severe aphasia, preventing subject from understanding the protocol and giving written consent\n13. Patients will be excluded postoperatively if there is neck swelling at the proposed site of left tcVNS.",{"count":344,"type":21},40,[24],"This study will examine whether noninvasive, transcutaneous vagal nerve stimulation (tcVNS) can help restore consciousness in patients in the operating room and the Post Anesthesia Care Unit (PACU). The study will also investigate if tcVNS can expedite discharge from the PACU and examine whether tcVNS administerd in the PACU helps reduce delirium and depression after surgery. The study will also evaluate whether tcVNS speeds cognitive recovery from emergence of anesthesia and surgery.",[348,30,349,350],"Post Operative Delirium","Vagus Nerve Stimulation","Depression",[352,353,354,349,355,356,350,357],"Anesthesia Care","Post Anesthesia Care","Post Surgical Care","Delirium","Cognitive Imparment","Hospital Length of Stay","2026-05-26",{"date":307,"type":40},{"date":361,"type":40},"2026-04-23",{"date":363,"type":21},"2029-05-31",{"name":365,"class":47},"Northwestern University",{"id":367,"slug":4,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":369,"acronym":4,"eligibilityCriteria":370,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":371,"targetDuration":4,"studyType":22,"phases":372,"briefSummary":374,"conditions":375,"keywords":378,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":105},"100543105","NCT06351540","Examining the Role of Tolerance on Dose-dependent Effects of Acute THC on Oculomotor and Cognitive Performance","Inclusion Criteria:\n\n* Inclusion criteria: Healthy non-treatment seeking adults (age 18 to 60, N = 40) who report\n* (a) infrequent cannabis use defined as at least one reported use in the past year with a negative THC urine toxicology at baseline, or\n* (b) report frequent cannabis use defined as \\> 5 days per week for \\> 1 year with a positive THC urine toxicology at baseline.\n\nThese criteria were selected to target individuals with low and high-frequency cannabis use in order to examine the direct effect of tolerance on study outcome measures.\n\nExclusion Criteria:\n\n* (1) meet DSM-V criteria for substance use disorders other than tobacco, cannabis, or caffeine,\n* (2) are currently receiving or interested in immediately receiving behavioral treatment or medication for cannabis cessation,\n* (3) current use of any medications that could affect study outcomes,\n* (4) test positive for drugs of abuse (other than cannabis) and\u002For breath alcohol test at study admission,\n* (5) have a current physical or mental illness judged by the study team to negatively impact participant safety or scientific integrity,\n* (6) are currently pregnant, planning to become pregnant in the next three months or are currently breastfeeding,\n* (7) have a history of clinically significant cardiac arrhythmias or vasospastic disease (e.g. Prinzmetal's angina), or (8) are currently enrolled in another clinical trial or have received any drug as part of a research study within 30 days of study participation.",{"count":344,"type":21},[373],"PHASE1","The purpose of this research is to determine the extent to which oculomotor function accurately detects THC-impairment, if cannabis use experience impacts this detection threshold, and to examine how the oculomotor index corresponds to a measure of sustained attention. A double-blind, placebo-controlled, within-subjects crossover design will be used to examine the dose-effects of THC (0, 5mg, 30mg) on oculomotor performance tasks and a sustained attention task in frequent and infrequent cannabis users. Results from the study will advance the investigators' understanding of the effect of THC and cannabis use frequency on oculomotor function and sustained attention, and will directly inform the validity of the investigators' oculomotor platform for identifying acute THC- induced impairment in frequent and infrequent users.",[376,377,30],"Cannabis Use","Impaired Driving",[379,380,381],"cannabis","THC","impairment",{"date":383,"type":40},"2026-05-27",{"date":385,"type":21},"2026-08-01",{"date":387,"type":21},"2027-07-01",{"name":211,"class":47},{"id":390,"slug":4,"hasResults":11,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":394,"eligibilityCriteria":395,"healthyVolunteers":15,"sex":16,"minAge":396,"maxAge":397,"enrollmentInfo":398,"targetDuration":4,"studyType":22,"phases":400,"briefSummary":401,"conditions":402,"keywords":408,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":419,"locationsCount":105},"100640111","NCT07615478","Effect of Hot Spring Therapy on Central Fatigue Elimination During Altitude Training","A Randomized Controlled Trial Investigating the Effects of Hot Spring Therapy Balneotherapy on Central Activation, Cognitive Function, and Exercise Performance in Adolescent Rowers During Altitude Training","HSCF-AHT","Inclusion Criteria:\n\n* Male or female aged 12-16 years- Healthy with no serious chronic diseases or skin conditions\n* At least 1 year of systematic rowing training experience\n* Currently undergoing centralized altitude training at approximately 1600 meters- No history of systematic hot spring or spa immersion within the past month\n* No allergy history to sodium bicarbonate or hot spring minerals- Ability to provide written informed assent (participant) and written informed consent (parent\u002Fguardian)- No acute infection, fracture, or surgery within the past month\n* Not currently taking non-steroidal anti-inflammatory drugs (NSAIDs), immunosuppressants, or medications affecting autonomic or cognitive function\n\nExclusion Criteria:\n\n* History of cardiovascular, respiratory, renal, endocrine, or neurological disorders- Uncontrolled hypertension or hypotension\n* History of syncope, heat intolerance, or severe dizziness during hot water immersion- Open wounds, severe eczema, or other skin conditions contraindicating water immersion\n* Current use of beta-blockers, anticholinergics, stimulants, sedatives, or other medications affecting central nervous system function\n* Color blindness or uncorrected visual impairment affecting Stroop test performance- Pregnancy (for female participants)- Alcohol consumption or smoking\n* Shift work or trans-meridian travel within 2 weeks prior to baseline assessment\n* Any condition deemed by the investigator as unsafe for participation","12 Years","16 Years",{"count":399,"type":21},27,[24],"This randomized controlled trial investigates the effects of hot spring balneotherapy on central fatigue elimination in adolescent rowers undergoing altitude training at approximately 1600 meters (Tengchong, Yunnan). Thirty adolescent athletes (aged 12-16 years) will be stratified by sex and randomly allocated to three groups: Group A (natural recovery, no immersion), Group B (38°C pure water immersion), and Group C (38°C sodium bicarbonate hot spring immersion). Interventions will be administered 3 times per week for 4 weeks. The primary outcomes are central fatigue indices including voluntary activation (VA) and central activation ratio (CAR). Secondary outcomes encompass cognitive function (Stroop test, Psychomotor Vigilance Test), cerebral hemodynamics (functional near-infrared spectroscopy, transcranial Doppler ultrasound), exercise performance (maximal oxygen uptake, 1000m test, 500m test), blood lactate, and hematological parameters (white blood cells, neutrophils, platelets).",[403,404,30,405,406,407],"Central Fatigue","Altitude Training","Hydrotherapy","Balneotherapy","Sports Performance",[409,410,405,411,412],"Altitude Sickness","Cognition","Hot Springs","Athletic Performance","2026-05-22",{"date":415,"type":40},"2026-05-29",{"date":417,"type":21},"2026-05-25",{"date":69,"type":21},{"name":420,"class":47},"Macao Polytechnic University",{"id":422,"slug":4,"hasResults":11,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":4,"eligibilityCriteria":426,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":427,"enrollmentInfo":428,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":430,"conditions":431,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":442,"locationsCount":105},"100411294","NCT04635657","Cognitive Status After Removal of Skull Base Meningioma","Pre and Post-Operative Cognitive Status in Patients Undergoing Surgery for Resection of Meningioma Associated With the Frontal and Temporal Lobes","Inclusion Criteria:\n\n* Subject has a meningioma associated with the frontal or temporal lobes\n* Subject is scheduled to undergo open craniotomy or Endoscopic Endonasal surgery\n* Subject is 18 years of age or older\n* The subject must in the investigator's opinion, be psychosocially, mentally, and physically able to fully comply with this protocol including the required follow-up visits, the filling out of required forms, and have the ability to understand and give written informed consent\n* Previous surgery will not exclude the patient as a new baseline cognitive evaluation will occur.\n\nExclusion Criteria:\n\n* Patient is a prisoner\n* Patient is 90 years of age or older\n* Pregnant women\n* Previous radiation to the brain","89 Years",{"count":429,"type":21},50,"The purpose of this prospectively enrolling trial is to assess long-term cognitive outcomes of patients undergoing surgery for resection of a meningioma associated with the frontal and temporal lobes.",[432,433,434,435,30,90,436],"Meningioma","Skull Base Meningioma","Frontal Meningioma","Temporal Meningioma","Post-Surgical Cognition","2026-05-19",{"date":413,"type":40},{"date":440,"type":40},"2019-12-10",{"date":44,"type":21},{"name":443,"class":47},"Ohio State University",{"id":445,"slug":4,"hasResults":11,"nctId":446,"briefTitle":447,"officialTitle":447,"acronym":4,"eligibilityCriteria":448,"healthyVolunteers":11,"sex":16,"minAge":449,"maxAge":189,"enrollmentInfo":450,"targetDuration":4,"studyType":22,"phases":452,"briefSummary":453,"conditions":454,"keywords":456,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":462,"completionDateStruct":463,"leadSponsor":465,"locationsCount":105},"100638257","NCT07605130","Efficacy and Safety Study of Digital Cognitive Training and PCSK9 Inhibitor-Enhanced Lipid-lowering Strategy in Patients With Intracranial Atherosclerotic Stenosis: A 2×2 Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age 55-80 years old\n2. The number of years of education is greater than or equal to 6 years\n3. 50%-99% stenosis of the intracranial artery confirmed by MRA, CTA or DSA\n4. Head CT or MRI confirmed that there were no infarct lesions\u002Fsoftening foci larger than 3 cm in the brain\n5. LDL-C ≥ 1.8mmol\u002FL at baseline\n6. Decline in cognitive function of the complainant\n7. MMSE ≥ 24 points; no severe impairment of daily living and social functioning, and the daily living ability scale (ADL, 14-item BADL and IADL combined version, total score range of 14-56 points) \\\u003C=18; and the investigator's clinical assessment does not meet the diagnosis of dementia (DSM-V or NIA-AA diagnostic criteria)\n8. Proficient in operating electronic products such as mobile phones and tablets\n9. Complete the operation evaluation through the introduction period (see the definition of the introduction period)\n10. Agree to receive maximally tolerated statin and PCSK9 inhibitor therapy during the study period\n11. Able to cooperate with neuropsychological and multimodal magnetic resonance examinations\n\nExclusion Criteria:\n\n1. Extracranial vascular stenosis ≥ 50%\n2. Acute cerebrovascular events within 90 days\n3. Contraindications to MRI (metal implants in the body, claustrophobia, etc.)\n4. Visual and auditory impairments, as well as communication difficulties, that affect cognitive training\n5. Clinically diagnosed vascular dementia\n6. Neuroimaging showing significant white matter lesions (Fazekas grade 3) or multiple microbleeds\n7. Non-atherosclerotic intracranial artery stenosis (such as vasculitis, moyamoya disease, dissection, etc.)\n8. Neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, etc.)\n9. Severe comorbidities (tumors, multiple sclerosis, severe cardiopulmonary and renal diseases, intracranial aneurysms)\n10. Other diseases that may affect cognition have been ruled out; severe anxiety, depression, or schizophrenia; a new stroke occurring within the 3 months prior to baseline; hereditary or inflammatory small vessel diseases; presence of any of the following clear sources of cardioembolic events: mitral stenosis, mechanical heart valves, endocarditis, intracardiac clots or vegetations, dilated cardiomyopathy, chronic or paroxysmal atrial fibrillation, ejection fraction less than 30%\n11. Planning to use medications that may affect cognitive function within the past 3 months or in the following 24 weeks, including large amounts of sedatives, anti-anxiety drugs, cognitive enhancers, and cholinergic agents.(12) Previously treated with a PCSK9 inhibitor\n12. Having a clear contraindication or severe intolerance to PCSK9 inhibitors or statins (such as a history of severe allergic reactions)\n13. Presence of significant liver or muscle safety abnormalities at baseline, or the investigator deems the patient unsuitable for intensive lipid-lowering therapy (for example, significantly elevated ALT or AST, significantly elevated CK, etc.; the thresholds can be based on the reference ranges of each center's laboratory and specified in the protocol in advance)\n14. Other circumstances deemed inappropriate for enrollment by the investigator","55 Years",{"count":451,"type":21},420,[300],"This study aims to evaluate whether digital cognitive training and\u002For intensive lipid-lowering therapy with a PCSK9 inhibitor can improve cognitive function in patients with intracranial atherosclerosis (ICAS).\n\nICAS is a common cause of stroke and is also linked to thinking and memory problems. The study will enroll 420 adults aged 55-80 years who have 50-99% narrowing of an intracranial artery, subjective memory complaints, and LDL cholesterol ≥1.8 mmol\u002FL, but who are not demented.\n\nParticipants will be randomly assigned to one of four groups in a 2×2 factorial design:\n\n1. No cognitive training + standard statin therapy\n2. Cognitive training + standard statin therapy\n3. No cognitive training + intensive statin plus PCSK9 inhibitor\n4. Cognitive training + intensive statin plus PCSK9 inhibitor\n\nCognitive training consists of 30 minutes of tablet-based exercises, 5 days per week for 12 weeks. The intensive lipid-lowering group receives a PCSK9 inhibitor (Recaticimab) injection at weeks 0, 4, and 12, on top of maximally tolerated statin.\n\nThe main outcome is change in a composite cognitive score from baseline to 24 weeks. Secondary outcomes include changes in specific cognitive domains, MRI markers of brain structure and function, and safety measures.\n\nThe study is multicenter, open-label with blinded outcome assessment, and is conducted under the approval of the ethics committee of Peking Union Medical College Hospital.",[455,30],"Intracranial Arteriosclerosis",[276,457,458,459],"Cognitive Training","Artificial Intelligence","Computerised Cognitive Training","2026-05-17",{"date":413,"type":40},{"date":417,"type":21},{"date":464,"type":21},"2029-07-31",{"name":466,"class":47},"Peking Union Medical College Hospital",{"id":468,"slug":4,"hasResults":11,"nctId":469,"briefTitle":470,"officialTitle":471,"acronym":472,"eligibilityCriteria":473,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":449,"enrollmentInfo":474,"targetDuration":4,"studyType":22,"phases":476,"briefSummary":478,"conditions":479,"keywords":481,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":486,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":492,"locationsCount":494},"100599464","NCT07084831","A Study Evaluating the Efficacy of Xanomeline\u002FTrospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia","A Prospective, Open-label, Single-arm, Multicenter Study Evaluating the Efficacy of Xanomeline\u002FTrospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia","SHINE","Inclusion criteria:\n\n1. Be between 18 and 55 years of age.\n2. Be willing and able to provide informed consent, after the nature of the study has been fully explained. This includes being able to understand the locally approved informed consent (and information letter) in the local language.\n3. Have a current DSM-5 diagnosis of schizophrenia, which needs to be confirmed by MINI.\n4. Have all PANSS positive items + G8 and G10 ≤4 at screening.\n5. Be on a stable dose of oral antipsychotic medication(s) for at least 4 weeks prior to Screening. Participants should be on monotherapy oral AP for baseline visit.\n6. Have a SCIP total below 70.\n7. Test negative for pregnancy at the screening visit and must be using a highly effective contraceptive method during the study and 30 days after the study, if being a female of childbearing potential.\n\nExclusion criteria:\n\n1. Be pregnant, lactating, or less than 3 months postpartum.\n2. Be at significant risk of committing suicide. This is defined as: participants with active suicidal ideation with some intent to act, without specific plan (\"Yes\" to question 4 of the Columbia-Suicide Severity Rating Scale (C-SSRS) or active suicidal ideation with specific plan and intent (\"Yes\" to question 5 of the C-SSRS), followed by an assessment by the treating clinician who determines it is not safe for the participant to participate in the study.\n3. Currently meet DSM-5 criteria for a manic episode or major depressive disorder as confirmed by the MINI.\n4. Currently meeting DSM-5 criteria for severe substance and\u002For alcohol use disorder as confirmed by the MINI (≥6 on module K for alcohol use disorder and\u002For ≥6 on module J for substance use disorder, unless being in early or sustained remission).\n5. Have a positive urine toxicology for phencyclidine, amphetamines, opiates (unless participant has a valid prescription for short-term use), cocaine, or alcohol (clinically significant alcohol use in the opinion of the Investigator). Nicotine and caffeine use is allowed. Stimulants and cannabis is allowed when used sporadically and recreationally as per the judgement of the clinician.\n6. Present with an intellectual disability, drug-induced psychosis, or history of clinically significant brain trauma as per the judgement of the clinician.\n7. Have current or past use of clozapine (used for at least 6 weeks in an effective dose range) and\u002For current use of a long-acting injectable antipsychotic, or anticholinergic treatment that cannot be discontinued before the baseline visit.\n8. Be expected to require more than the allowed psychotropic concomitant medication during the study (from baseline on). This is defined as: needing benzodiazepines of more than 2 mg lorazepam equivalent (daily), quetiapine, antidepressants, mood stabilizers or benzodiazepines at a dose exceeding the allowed threshold. If these treatments are used at the screening visit, they must be tapered down before the baseline visit.\n9. Have clinically significant abnormal finding on the physical examination, medical history, ECG (at screening), or clinically significant laboratory results at screening.\n10. Participated in any cognitive remediation\u002Ftraining program or completed the BACS within 4 weeks of Screening.\n11. Having a known allergy to xanomeline, trospium chloride or any of the ingredients of XT.\n12. Have current presence of clinically significant cardiovascular, pulmonary, renal, hematologic, gastrointestinal (e.g., obstructive disorders \\[including conditions that may decrease GI motility, such as ulcerative colitis, intestinal atony, and myasthenia gravis\\], endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the participant or the validity of the study results. This includes:\n\n12a. Have history or high risk of urinary retention. 12b. All grades of hepatic impairment (mild \\[Child-Pugh Class A\\], moderate \\[Child-Pugh Class B\\], and severe \\[Child-Pugh Class C\\]).\n\n12c. Elevations in hepatic transaminases at screening ≥ 2× ULN for ALT and AST and\u002For bilirubin \\> 2 × ULN, unless in the context of Gilbert's syndrome.\n\n12d. Have a history or high risk for narrow-angle glaucoma. 12e. Active biliary disease (e.g., symptomatic gallstones). Participants with other biliary histories are eligible and should be discussed with the sponsor.\n\n12f. Participants with a history of bladder stones . 12g. Participants with a history of recurrent urinary tract infections. 12h. For all male participants, serum prostate-specific antigen \\>10 ng\u002FmL at screening.\n\n12i. For male participants ≥ 45 years of age, an IPSS score of 5 (i.e, \"almost always\") on items 1, 3, 5, or 6, and\u002For for male participants ≥ 45 years of age, an IPSS score ≥ 9 for the sum of items 1, 3, 5, and 6.\n\n12j. An eGFR of \\\u003C 60 mL\u002Fmin (which indicates renal dysfunction). 12k. History of unstable hypertension or tachycardia as evidenced by a blood pressure of ≥ 160\u002F100 mmHg at screening and\u002For a heart rate of ≥ 110 bpm at screening.",{"count":475,"type":21},171,[477],"PHASE3","Schizophrenia is a long-lasting and serious mental health disorder that affects about 1% of people worldwide. It can cause symptoms such as hallucinations and delusions (called positive symptoms), confused or disorganized thinking, reduced motivation and emotional expression (negative symptoms), difficulties with memory and concentration (cognitive symptoms), and movement problems like restlessness or slowed activity. Current treatments, called antipsychotics, mainly work by blocking dopamine in the brain. These medicines are helpful for hallucinations and delusions, but they do little to improve negative or cognitive symptoms.\n\nA new medicine, Xanomeline\u002FTrospium (XT), works differently. It targets a brain system called the muscarinic acetylcholine receptors while limiting side effects elsewhere in the body. Clinical trials have shown that XT reduces psychotic symptoms effectively and is generally well tolerated. The FDA approved XT in 2024 for adults with schizophrenia. Importantly, early results also suggest that XT may help improve thinking and memory (cognition domains), though this has not yet been studied in depth.\n\nMost schizophrenia drug studies pay little attention to long-term changes in cognition, often using only short screening tests. This study will be the first to take a deep look at cognitive function over a full year of XT treatment. It will also examine how changes in thinking skills connect with other aspects of life, such as symptom control, daily functioning, and quality of life. By making cognition a central outcome, the study responds to an urgent need in schizophrenia research: moving beyond just controlling hallucinations and delusions toward improving real-world recovery. The results could help shape future treatment strategies and support the idea that cognition should be a core treatment target in schizophrenia.",[480,30],"Schizophrenia; Psychosis",[482,483,484],"functioning","quality of life","speech analyses","2026-05-12",{"date":487,"type":40},"2026-05-13",{"date":489,"type":21},"2027-01-01",{"date":491,"type":21},"2029-07-01",{"name":493,"class":47},"European Group for Research In Schizophrenia",16,{"id":496,"slug":4,"hasResults":11,"nctId":497,"briefTitle":498,"officialTitle":498,"acronym":499,"eligibilityCriteria":500,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":501,"targetDuration":4,"studyType":22,"phases":502,"briefSummary":503,"conditions":504,"keywords":509,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":515,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":4},"100485768","NCT05605366","Minocycline In Neurocognitive Outcomes - Sickle Cell Disease","MINO-SCD","Inclusion Criteria:\n\nAdults (age ≥ 18 years old) with SCD (HbSS and HbS-β0thalassemia genotypes only) who are followed at the University of Cincinnati Medical Center's SCD clinic are eligible to participate. As hydroxyurea is the standard-of-care in SCD, individuals on hydroxyurea will be included\n\nExclusion Criteria:\n\n1. adults with other SCD genotypes (HbSC or HbS- β+thalassemia),\n2. individuals with a history of overt stroke or other known neurological disorder,\n3. premature birth before 30 weeks gestation,\n4. monthly therapy with chronic blood transfusions,\n5. coexisting autoimmune condition due to an elevated risk for autoimmune-related complications with tetracyclines,\n6. tetracycline allergy.\n7. Women who are pregnant or breast-feeding",{"count":266,"type":21},[373],"Sickle cell disease (SCD) is a common, inherited blood disorder that primarily affects people of African Ancestry. It has a lot of complications including neurological complications. The neurological complications of SCD are particularly devastating and lead to cognitive decline even in the absence of overt brain injury. In such cases, it is thought that inflammation in the brain maybe partly responsible for the cognitive decline.\n\nThe main reasons for this research study are to see 1) how safe and 2) how well minocycline works to try to stop\u002Freverse cognitive decline in people with SCD. People with SCD are at risk for changes in their brain over time that can cause problems with learning, memory, and attention. Part of the reason for this is inflammation within the brain. Minocycline may be able to stop these brain changes by stopping this brain inflammation.\n\nMinocycline is a second-generation tetracycline antibiotic that has been shown to both inhibit neuroinflammation and improve cognitive function in a variety of neurodegenerative and psychiatric disorders but has not yet been studied in SCD. We are proposing here, a pilot double-blinded, randomized controlled trial to examine the tolerability and early efficacy of minocycline in adults with SCD at two dosing regimens (200 mg and 300 mg daily) versus placebo over one year. Participants will undergo a neuropsychological exam using the NIH Toolbox Cognition Battery at both study enrollment and exit (after one year) to assess for changes\u002Fstability of cognition. Participants will receive monthly phone calls\u002Ftext messages to assess for adverse events and will be seen every three months for pill counts and routine laboratory monitoring. The primary outcome will be a comparison of adverse events across the two dosing strategies versus placebo. Early evidence for cognitive benefit will also be assessed from the results of the NIH Toolbox.",[505,30,90,506,276,507,508],"Sickle Cell Disease","Cognitive Change","Cognitive Deficit","Neuroinflammatory Response",[510,511,512,513],"sickle cell disease","benign hematology","cognitive dysfunction","neuroinflammation","2026-05-11",{"date":516,"type":40},"2026-05-14",{"date":518,"type":21},"2026-12-01",{"date":520,"type":21},"2028-06-15",{"name":522,"class":47},"University of Cincinnati",{"id":524,"slug":4,"hasResults":11,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":528,"eligibilityCriteria":529,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":530,"targetDuration":4,"studyType":22,"phases":532,"briefSummary":533,"conditions":534,"keywords":541,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":553,"locationsCount":105},"100637070","NCT07585500","Virtual Reality for Recovery After Intensive Care (PICS)","Virtual Reality Intervention for Post-Intensive Care Syndrome (PICS): A Protocol for a Pilot Randomized Controlled Trial for Cognitive, Physical and Psychological Outcomes","VR4ICU","Inclusion Criteria:\n\n* Adult patients, 18 years or older\n* Patients in the Intensive Care Unit\n* Ventilated patients must be in the post-extubation period\n* The patient has a projected remaining hospital stay of at least 4 days (assessed by the clinical team)\n* The patient has RASS score between -1 and +1\n* The patient has the ability to move both arms, even if with difficulties, as assessed by the clinical team, to be able to interact with the software\n* The patient can maintain a stable sitting position (30° to 60°)\n* The patient is able to communicate (speech, gesturing, or writing)\n* The patient can communicate and understand Portuguese\n* The patient or a legal representative provided informed consent\n\nExclusion Criteria:\n\n* Severe cognitive and neurodegenerative diseases: mental illness requiring institutionalization; acquired or congenital intellectual disability; known severe brain injuries (e.g., stroke with significant residual deficits); moderate to severe Traumatic Brain Injury (TBI) (defined by the duration of loss of consciousness\u002Fpost-traumatic amnesia or documented residual deficits); diagnosed neurodegenerative diseases (e.g., Parkinson's disease with severe movement impairment, Huntington's disease, severe Alzheimer's disease, or dementia of any etiology that prevents autonomy in daily life at baseline)\n* The patient uses neuromuscular blocking agents\n* The patient has a positive CAM-ICU result at the time of initial screening\n* The patient has active psychotic disorders or suicidal ideation\n* The patient has documented epilepsy or history of seizures\n* The patient has a \"Do Not Resuscitate\" (DNR) order, is on life support with exclusive focus on comfort, or has an unexpected survival predicted to be less than 24 hours\n* The patient has intoxication by an active substance or withdrawal syndrome requiring ongoing medical management that prevents safe and meaningful participation or accurate cognitive assessment\n* Patients with immobility or severe motor limitations in the upper limbs, fine motor skills, or cervical region\n* The patient has open wounds on the head or face that may affect the comfortable\u002Fsafe use of VR glasses, cause discomfort, or present a hygiene risk\n* The patient has uncorrected blindness or deafness that prevents the safe\u002Feffective use of VR\u002Ftablet devices.\n* Patients are participating in another rehabilitation study with interventions\n* Patients with a scheduled surgery where the ICU stay is expected to be less than 24 hours\n* Patients in need of respiratory support",{"count":531,"type":21},51,[24],"The goal of this clinical trial is to learn if virtual reality (VR) helps improve thinking and memory skills in adults who have stayed in the intensive care unit (ICU). The study focuses on people who needed a breathing machine or stayed in the ICU for several days and are at risk for memory or \"brain fog\" issues.\n\nThe main questions it aims to answer are:\n\n* Does using VR improve a participant's memory, attention, and thinking skills after an ICU stay?\n* Does the \"immersive\" feel of a VR headset work better to improve these skills than using a handheld tablet?\n\nResearchers will compare three groups to see how different types of care affect the brain:\n\n* VR-Rehab: Participants use a VR headset to play brain-training games.\n* Tablet-Rehab: Participants use a handheld tablet to play the same brain-training games.\n* Standard Care: Participants receive the usual hospital care without digital brain games.\n\nParticipants will:\n\n* Play brain-training games for 12 minutes every day for up to one week while in the hospital.\n* Complete memory and thinking tests with a researcher at the start of the study and again after two weeks.\n* Answer follow-up questions about their memory and thinking skills for 6 months after leaving the hospital.",[535,536,537,538,30,539,540],"Post-Intensive Care Syndrome (PICS)","Critical Illness Recovery","Rehabilitation After Critical Illness","Rehabilitation Exercise of ICU Patients","Critical Illness","Intensive Care Unit (ICU)",[535,30,539,542,543,544,540,545,546,547,35],"Virtual Reality (VR)","Digital Health","Rehabilitation","Critical Care","ICU Survivors","Pilot Study","2026-05-08",{"date":487,"type":40},{"date":551,"type":40},"2025-12-06",{"date":286,"type":21},{"name":554,"class":47},"University of Minho",{"id":556,"slug":4,"hasResults":11,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":4,"eligibilityCriteria":560,"healthyVolunteers":15,"sex":561,"minAge":562,"maxAge":188,"enrollmentInfo":563,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":564,"conditions":565,"keywords":566,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":105},"100385308","NCT04297020","Brain Health in Breast Cancer Survivors","Brain Health in Breast Cancer Survivors: Interaction of Menopause and Endocrine Therapy","Inclusion Criteria:\n\n* Age 35-65\n* Fluent in English\n* Adequate vision\u002Fhearing to complete testing\n\nExclusion Criteria:\n\n* History of major or mild neurocognitive disorder or dementia\n* Diagnosis of major neurological condition (e.g., epilepsy, Parkinson's Disease, stroke)\n* Diagnosis of a major psychiatric disorder (e.g., bipolar disorder, schizophrenia)\n* Untreated\u002Funstable unipolar depression or anxiety\n* Prior history of cancer or chemotherapy (for controls, any history)\n* History of a learning disorder\n* History of head injury with loss of consciousness \\>20 minutes\n* History of salpingo-oophorectomy or hysterectomy\n* A cardiac pacemaker\n* Implanted electronic device\n* Claustrophobia\n* Currently pregnant\n* Orbital metal implant or other metallic foreign bodies\n\nAdditional exclusion criteria for controls: current use of a contraceptive agent that interferes with endogenous hormonal fluctuation (e.g., oral contraceptive pill) or precludes determination of menstrual pattern (e.g., hormonally secreting intrauterine device), or current treatment with systemic estrogen replacement therapy.","FEMALE","35 Years",{"count":20,"type":21},"Endocrine therapy (ET) is widely used to treat hormone receptor positive breast cancer and prevent recurrence by downregulating estrogen function. However, ETs readily cross the blood brain barrier and interfere with the action of estrogen in the brain. Estrogen supports cognition and menopausal status is closely linked to cognitive health in women. This has raised concern that anti-estrogen ETs may affect cognition and brain health in breast cancer survivors. However, evidence across existing studies is inconsistent and these effects remain poorly understood. The incomplete understanding of the effects of ET are likely due to limitations of earlier studies - namely, the under-appreciation of the role of menopausal status and insensitivity of standard cognitive measures. This research project will address these earlier limitations by specifically comparing ET effects by menopausal status, and using highly sensitive, task-related functional magnetic resonance imaging (fMRI) measures to assess the effects of ET on brain function.",[30,63],[567,568],"Breast cancer","endocrine therapy","2026-05-07",{"date":514,"type":40},{"date":572,"type":40},"2020-03-11",{"date":574,"type":21},"2028-03-15",{"name":576,"class":47},"Jonsson Comprehensive Cancer Center",{"id":578,"slug":4,"hasResults":11,"nctId":579,"briefTitle":580,"officialTitle":581,"acronym":582,"eligibilityCriteria":583,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":584,"enrollmentInfo":585,"targetDuration":4,"studyType":22,"phases":587,"briefSummary":588,"conditions":589,"keywords":592,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":599,"lastUpdatePostDateStruct":600,"startDateStruct":601,"completionDateStruct":602,"leadSponsor":604,"locationsCount":4},"100609916","NCT07220798","Improving Self-Care of Caregivers of Adults in Homecare With Heart Failure and Cognitive Impairment","Improving Self-Care of Caregivers of Adults in Homecare With Heart Failure and Cognitive Impairment (iCare4Me Homecare)","iCare4Me HC","Inclusion Criteria:\n\n* Patient Inclusion Criteria\n\n  1. Older adults (=\\>50 years of age)\n  2. Enrolled in Home Health Care\n  3. Documented to have HF\n  4. Mild to moderate CI on the BIMS or OASIS items\n  5. Able to provide informed consent\n  6. Able to provide self-report data\n* Caregiver Inclusion Criteria\n\n  1. Adults (=\\>18 years of age)\n  2. Spouse\u002Fpartner or child living with or in close proximity to the patient\n  3. Caregiver of a home care patient who is currently receiving or recently received services and who has mild to severe cognitive impairment\n  4. Reporting poor self-care on screening (Health Self-Care Neglect scale score =\\>2)\n  5. Reporting poor mental health on screening (screened with the PROMIS Global Mental Health 4a score \\\u003C12)\n  6. Caregiving or supporting the patient at least 8 hours\u002Fweek\n  7. Able to complete the protocol, e.g., adequate vision and hearing, English speaking.\n  8. Able to provide informed consent\n  9. Able to use technology\n\nExclusion Criteria:\n\n* Patient Exclusion Criteria\n\n  1. Dementia (ICD-10 code for dementia)\n  2. Enrolled in hospice\n  3. Non-English speaking\n* Caregiver Exclusion Criteria 1. Non-English speaking","101 Years",{"count":586,"type":21},316,[24],"This RCT design will enroll 256 informal caregivers (spouse\u002Fpartner or child) of HHC patients with HF\u002FCI and 60 patients with HF and mild to moderate CI (60 dyads). After collecting baseline data, we will block randomize the caregivers 1:1 to the ViCCY intervention or comparator group, stratifying randomization by caregiver sex (male\u002Ffemale), relationship (spouse\u002Fpartner or child), and race (white\u002Fother)- factors known to influence caregiving burden, perceived stress, and receptivity to the intervention. We will encourage caregivers to use their own devices but provide tablet devices with wireless network access if needed. The intervention group will receive 10 sessions of ViCCY over 6 months.",[590,30,591],"Heart Failure","Caregiver Burden",[593,594,595,596,597,598],"heart failure","cognitive impairment","caregiver burden","caregiver stress","self-care","dyads","2026-05-06",{"date":548,"type":40},{"date":254,"type":21},{"date":603,"type":21},"2029-09-15",{"name":605,"class":47},"Visiting Nurse Service of New York",{"id":607,"slug":4,"hasResults":11,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":4,"eligibilityCriteria":611,"healthyVolunteers":11,"sex":16,"minAge":612,"maxAge":613,"enrollmentInfo":614,"targetDuration":4,"studyType":22,"phases":616,"briefSummary":617,"conditions":618,"keywords":619,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":624,"lastUpdatePostDateStruct":625,"startDateStruct":626,"completionDateStruct":628,"leadSponsor":629,"locationsCount":105},"100640942","NCT07578896","Maze Balance Board Training Effects on Mobility and Motor Skills in Cognitively Impaired Children","Effects of Maze Balance Board Training on Functional Mobility and Gross Motor Skills in Children With Cognitive Impairment","Inclusion Criteria:\n\n* Children aged 6-10 years\n* Mild to Moderate Cognitive Impairment (MoCA score =18 to 25)\n* Gross motor skill delay (10).\n* Ability to follow verbal instructions\n* Parents are willing to make sure their child's participation\n\nExclusion Criteria:\n\n* Use of medications that may influence neuromotor functions (e.g., sedatives, antiepileptic's)\n* Children with visual and hearing impairments\n* Receiving concurrent therapies\n* Recent lower limb injuries , surgeries, or musculoskeletal conditions","6 Years","10 Years",{"count":615,"type":21},22,[24],"The study will be a Randomized Controlled Trial including 22 children aged 6-10 years with deficits in functional mobility and gross motor skills. Participants will be randomly divided into an experimental group (n=11), receiving a seven-stage progressive Maze Balance Board protocol, and a control group (n=11), receiving conventional physical therapy. Both groups will undergo 30-minute sessions, three times per week, for 8 weeks. Eligible participants will be enrolled after guardian consent. Outcomes will be assessed using the Montreal Cognitive Assessment (MoCA) for cognition, Timed Up and Go (TUG) test for functional mobility, and Bruininks-Oseretsky Test of Motor Proficiency, Second Edition (BOT-2) for gross motor skills. Ethical approval will be obtained from Riphah International University, Lahore, and data will be analyzed using SPSS version 27.0.",[30],[620,621,622,623],"Cognitive impairment","Functional mobility","Gross motor skills","Maze balance board","2026-05-05",{"date":514,"type":40},{"date":627,"type":40},"2025-10-28",{"date":254,"type":21},{"name":630,"class":47},"Riphah International University",{"id":632,"slug":4,"hasResults":11,"nctId":633,"briefTitle":634,"officialTitle":634,"acronym":635,"eligibilityCriteria":636,"healthyVolunteers":15,"sex":16,"minAge":637,"maxAge":4,"enrollmentInfo":638,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":639,"conditions":640,"keywords":646,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":652,"lastUpdatePostDateStruct":653,"startDateStruct":654,"completionDateStruct":655,"leadSponsor":657,"locationsCount":105},"100629097","NCT07470216","Cognitive Assessment And Post-Operative Complications After Surgery: Linking Anaesthesia And Risk","CAPSULAR","Inclusion Criteria:\n\n* Age ≥ 70\n* Seen in the Perioperative medicine for Older People undergoing Surgery (POPS) clinic\n* Scheduled for colorectal or urological surgery with expected anaesthesia time over 60 minutes\n\nExclusion Criteria:\n\n* Regional anaesthesia only\n* Planned day surgery or expected hospital stay \\\u003C 24 hours\n* Expected to remain sedated and ventilated for \\> 24 hours postoperatively\n* Participant does not wish to remain in the study if capacity is lost during the study\n\nCO-ENROLMENT\n\n* As this is a non-intervention study, co-enrolment will be permitted in other studies that do not conflict with this protocol.","70 Years",{"count":344,"type":21},"Many older people can experience confusion, memory problems, or a decline in their thinking after major surgery. These problems are sometimes called 'postoperative neurocognitive disorders' or PND and can affect recovery and a person's ability to live independently.\n\nThe investigators want to find out the best way to study these problems in older patients undergoing surgery. This is a 'feasibility study', which means we are testing the research methods. The investigators want to see if it is possible to ask participants to do memory tests and give blood samples before and after their operation. The investigators are hoping to include around 40 patients over 2 years in this study.\n\nThe investigators will compare performance in memory (cognitive assessment) findings before and after surgery and link this to data taken from the anaesthetic, including the types of drugs used, duration, brain features from processed electroencephalogram monitoring and standard recommended monitoring. In addition the investigators will link this to blood sample markers of brain health and function (biomarkers).\n\nThe results of this study will help the investigators plan a much larger study in the future, with the ultimate goal of making surgery safer for the brain.",[30,641,642,643,644,645],"Cognitive Impairment, Mild","Cognitive Impairment, Progressive","Anesthesia","Anesthesia Brain Monitoring","Anesthesia Depth Monitoring",[594,647,648,649,650,651],"cognitive impairment, mild","cognitive impairment, progressive","anesthesia","anesthesia brain monitoring","anesthesia depth monitoring","2026-05-04",{"date":548,"type":40},{"date":71,"type":21},{"date":656,"type":21},"2028-03",{"name":658,"class":47},"University of Edinburgh",{"id":660,"slug":4,"hasResults":11,"nctId":661,"briefTitle":662,"officialTitle":662,"acronym":4,"eligibilityCriteria":663,"healthyVolunteers":11,"sex":561,"minAge":17,"maxAge":4,"enrollmentInfo":664,"targetDuration":4,"studyType":22,"phases":666,"briefSummary":668,"conditions":669,"keywords":675,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":681,"lastUpdatePostDateStruct":682,"startDateStruct":683,"completionDateStruct":685,"leadSponsor":687,"locationsCount":105},"100572016","NCT06727773","Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer","Inclusion Criteria:\n\nIn order to participate in the study a subject must meet all of the eligibility criteria outlined below.\n\n* Female\n* Age ≥ 18 years at the time of consent.\n* Stage I-III Breast Cancer\n* Recommended chemotherapy\n* Enroll prior to 3rd cycle of chemotherapy\n* English-speaking\n\nExclusion Criteria:\n\n* Allergy to memantine\n* Previous chemotherapy (prior to the current regimen),\n* Severe cognitive impairment, defined by Blessed Orientation Memory Concentration Test Score ≥11\n* Myocardial infarction in the last 6 months\n* Cardiovascular or orthopedic limitations to exercise\n* Severe mental illness (i.e., schizophrenia or bipolar affective disorder)\n* Current alcohol or drug abuse\n* Inability to swallow capsules \\\u003C\u002F= 5mL\u002Fmin\n* CrCl \\\u003C\u002F= 5mL\u002Fmin",{"count":665,"type":21},90,[667],"PHASE2","This randomized, placebo-controlled trial aims to assess the feasibility, acceptability, and preliminary efficacy of memantine and the University of Carolina (UNC)'s Get Real \\& Heel cancer exercise program (MEM+EX) in addressing cancer-related cognitive impairment (CRCI) and underlying CRCI biomarkers. Ninety stage I-III breast cancer patients during chemotherapy will be randomized into three groups: MEM+EX, memantine, or placebo. The study will evaluate recruitment, retention, adherence, acceptability, cognitive function, brain-derived neurotrophic factor (BDNF), inflammatory markers, and frailty at multiple time points.",[670,671,30,90,506,672,673,674],"Breast Cancer","Locally Advanced Breast Cancer","Breast Cancer Stage I","Breast Cancer Stage II","Breast Cancer Stage III",[676,677,678,679,680],"chemotherapy","memantine","placebo-controlled","exercise","Get Real & Heel cancer exercise program","2026-05-01",{"date":599,"type":40},{"date":684,"type":40},"2025-08-19",{"date":686,"type":21},"2029-06-15",{"name":688,"class":47},"UNC Lineberger Comprehensive Cancer Center",{"id":690,"slug":4,"hasResults":11,"nctId":691,"briefTitle":692,"officialTitle":693,"acronym":694,"eligibilityCriteria":695,"healthyVolunteers":15,"sex":16,"minAge":188,"maxAge":4,"enrollmentInfo":696,"targetDuration":4,"studyType":22,"phases":698,"briefSummary":699,"conditions":700,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":681,"lastUpdatePostDateStruct":704,"startDateStruct":705,"completionDateStruct":707,"leadSponsor":709,"locationsCount":105},"100506654","NCT05877196","A SMART Trial of Adaptive Exercises to Optimize Aerobic-Fitness Responses","Precision Medicine in Alzheimer's Disease: A SMART Trial of Adaptive Exercises and Their Mechanisms of Action Using AT(N) Biomarkers to Optimize Aerobic-Fitness Responses (The FIT-AD SMART Trial)","SMART","Inclusion Criteria:\n\nParticipants:\n\n* Clinical diagnosis of MCI or probable and possible mild AD dementia according to 2011 Alzheimer's association-NIA criteria.\n* Community-dwelling, e.g., homes and assisted living\n* Age 65 years and older\n* Medical clearance from PCP or cardiovascular provider\n* Have a qualified study partner\n* Agree to the blood draws\n* Verified MRI safety\n\nStudy Partner:\n\n* Age 18 or older\n* Contact with participant ≥ 2 times per week for ≥ 6 months\n* Know the participant's memory status and ability to perform activities of daily living\n* Consent to participant\n\nExclusion Criteria:\n\nParticipants\n\n* Resting HR ≤ 50 or ≥ 100 beats\u002Fmin after 5-minutes of quiet resting\n* American College of Sports Medicine contraindications to exercise\n* New, unevaluated symptoms or diseases a healthcare provider has not evaluated\n* Abnormal cardiac condition uncovered during VO2peak testing\n* Enrollment in another intervention that aims at improving cognition\n* Moderate to strenuous exercise ≥150 minutes a week in the previous 6 months\n* ≥ 2 anti-depression medications, or poorly managed or unstable depression\n* Poorly managed or unstable anxiety\n\nStudy partners:\n\n* none",{"count":697,"type":21},216,[24],"The goal of this clinical trial is to test 6 months of aerobic exercise in older adults who are 65 years or older and have mild cognitive impairment (MCI) or probable\u002Fpossible mild Alzheimer's Disease. The main questions it aims to answer are:\n\n* test the effects of aerobic exercise on aerobic fitness, white matter hyperintensity (WMH) volume, and patient-centered outcomes;\n* identify the best exercise to improve aerobic fitness and reduce non-responses over 6 months; and\n* examines the mechanisms of aerobic exercise's action on memory in older adults with early AD.\n\nParticipants will receive 6 months of supervised exercise, undergo cognitive data collection and exercise testing 5 times over a year span, have an MRI brain scan 3 times over a one-year span, and have monthly follow-up discussions on health and wellness.",[701,161,30,90,702,703],"Mild Cognitive Impairment","Memory Loss","Memory Impairment",{"date":624,"type":40},{"date":706,"type":40},"2023-06-22",{"date":708,"type":21},"2028-06-30",{"name":710,"class":47},"Arizona State University",""]